Core Viewpoint - The company has announced that it has not yet implemented its share repurchase plan, which is now more than halfway through its designated period [1][2]. Group 1: Share Repurchase Plan - The company approved a share repurchase plan with a total fund amount between RMB 15 million and RMB 30 million, with a maximum repurchase price of RMB 25.00 per share [1]. - The upper limit of the repurchase price has been adjusted to RMB 24.80 per share, effective from July 10, 2025 [2]. - As of the announcement date, the company has not executed any repurchases due to considerations of its operational status and market conditions [2]. Group 2: Future Repurchase Arrangements - The company plans to proceed with the share repurchase within the designated period and will adhere to relevant regulations and disclosure obligations [2].

二、后续回购安排 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 1 月 24 日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）召开第四届董事会第二次会议，审议通过了《关于第二期以集中竞价交易 方式回购公司股份方案的议案》，同意公司使用自有资金和回购专项贷款以集中 竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，并在未来适宜 时机用于实施股权激励计划，回购资金总额不低于人民币 1,500 万元（含），不 超过人民币 3,000 万元（含），回购价格不超过 25.00 元/股（含），回购股份的期 限为自公司董事会审议通过第二期以集中竞价交易方式回购公司股份方案（以下 简称"第二期回购方案"）之日起不超过 12 个月。具体内容详见公司于 2025 年 2 月 7 日在上海证券交易所网站(www.sse.com.cn)上披露的《嘉必优生物技术（武 汉）股份有限公司关于第二期以集中竞价交易方式回购公司股份的回购报告书》 （公告编号：2025-008）。 2025 年 7 月 10 日，因公司实 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has exceeded expectations in its H1 2025 performance, with a projected revenue of 307 million yuan, representing a year-on-year increase of 17.6%. The net profit attributable to the parent company is expected to be 107 million yuan, reflecting a growth of 57.6% [2] - The company is expected to maintain high revenue levels, driven by new national standards and an increase in international market orders. The revenue for Q2 2025 is projected to be approximately 151 million yuan, a year-on-year increase of about 5.6% [3] - The company is experiencing significant profit growth, with Q2 2025 profits expected to exceed market expectations due to the scale effect from increased DHA production and reduced costs, leading to improved gross margins [4] - The acquisition target, Ouyi Biological, is expected to contribute significantly to the company's growth, with a commitment to a cumulative net profit of no less than 270 million yuan from 2025 to 2027 [5] Financial Summary - The company forecasts revenues of 708 million yuan in 2025, with a year-on-year growth of 27.4%. The net profit attributable to the parent company is projected to be 192 million yuan, reflecting a growth of 54.2% [10] - The gross margin is expected to improve to 48.1% in 2025, with a net margin of 27.1% [10] - The earnings per share (EPS) is forecasted to be 1.14 yuan in 2025, with a price-to-earnings (P/E) ratio of 23.9 [10][11]

Group 1 - The company expects to achieve an operating income of approximately 307 million yuan in the first half of 2025, representing a year-on-year growth of 17.59% [1] - The net profit attributable to the parent company is projected to be around 107 million yuan, an increase of 57.61% compared to the same period last year [1] - The increase in performance is attributed to the rise in sales of core products ARA and algal oil DHA, along with improved production efficiency and optimization of product and customer structure, enhancing the company's profitability [1] Group 2 - In 2024, the company reported an operating income of 556 million yuan, a year-on-year increase of 25.19% [3] - The net profit attributable to the parent company for 2024 is 124 million yuan, reflecting a growth of 35.94% [3] - The net profit after deducting non-recurring gains and losses is approximately 100 million yuan, which is a 60.11% increase year-on-year [3] Group 3 - The chairman and general manager, Yi Dewei, has held various significant positions since 1987, including roles in educational and cultural organizations, and has been with the company since its inception [3] - Yi Dewei's compensation from 2020 to 2024 has shown slight fluctuations, with the highest being 118.0 thousand yuan in 2022 [3] - Vice chairman Du Bin has also held multiple roles in educational and corporate settings since 1987, serving as vice chairman since December 2015 [4] - Du Bin's compensation from 2020 to 2024 has increased over the years, peaking at 99.07 thousand yuan in 2022 [4]

Core Viewpoint - The company, Jia Bi You, is expected to achieve significant revenue and profit growth in the first half of 2025, driven by increased sales of its core products and the recent approval of its product, N-acetylneuraminic acid, for use in cosmetics and food [1][4][5]. Financial Performance - Jia Bi You anticipates a revenue of approximately 307 million yuan for the first half of 2025, representing a year-on-year increase of about 17.59% [1][2]. - The company expects a net profit attributable to shareholders of around 107 million yuan, reflecting a growth of 57.61% compared to the same period in 2024 [1][2]. - In the first quarter of 2025, Jia Bi You reported a revenue of 156 million yuan, a year-on-year increase of 33.28%, and a net profit of approximately 44.99 million yuan, up 85.07% year-on-year [2][3]. Product Development and Market Position - The increase in revenue is primarily attributed to higher sales of core products ARA and DHA, along with improved production efficiency and optimized product and customer structures [3]. - Jia Bi You's gross margin for 2024 was 43.61%, an increase of 1.22 percentage points year-on-year, while the net profit margin was 21.62%, up 2.16 percentage points from the previous year [2]. Regulatory Approval and Market Expansion - N-acetylneuraminic acid, a product of Jia Bi You's subsidiary, Zhongke Guanggu, has been officially included in the cosmetics raw material directory, marking a significant regulatory milestone [4][5]. - This approval allows Jia Bi You to leverage its technological advantages in synthetic biology to innovate within the health and beauty sectors, potentially leading to new trends in the industry [5]. - The company is also advancing its capabilities through the acquisition of Ouyi Biotechnology, aiming to enhance its technical service offerings and create an integrated service platform [5].

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 证券代码：688089 证券简称：嘉必优 公告编号：2025-056 嘉必优生物技术（武汉）股份有限公司 关于 2025 年半年度业绩预增的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 经财务部门初步测算： 1、2025 年半年度实现营业收入约 30,670 万元，较上年同期增长 17.59%； 2、2025 年半年度实现归属于母公司所有者的净利润约 10,700 万元，较上年 同期增长 57.61%； 3、2025 年半年度实现归属于母公司所有者的扣除非经常性损益的净利润约 9,300 万元，较上年同期增长 75.45%。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 1、2024 年半年度营业收入：26,083.24 万元； 2、2024 年半年度利润总额：7,803.82 万元； 四、风险提示 公司本次业绩预告数据未经注册会计师审计，为 ...

Core Viewpoint - The company reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and growth in key product sales [1] Financial Performance - The company achieved a revenue of approximately 307 million yuan, representing a year-on-year growth of 17.59% [1] - The net profit attributable to the parent company was around 107 million yuan, reflecting a year-on-year increase of 57.61% [1] - The net profit excluding non-recurring gains and losses was approximately 93 million yuan, which is a 75.45% increase compared to the same period last year [1] Operational Drivers - The increase in revenue was primarily driven by higher sales volumes of core products ARA and algal oil DHA [1] - Profit growth was attributed to the rise in revenue, improved production efficiency, and optimization of product and customer structures, enhancing the company's profitability [1]

Core Viewpoint - The article discusses the emerging significance of Extracellular Matrix (ECM) in anti-aging skincare, highlighting the potential of N-acetylneuraminic acid (also known as "Nectar Acid") as a key ingredient in this new approach to skincare [2][3][15]. Group 1: ECM and Anti-Aging - ECM has been identified as the thirteenth hallmark of aging, representing a new pathway for anti-aging technology in the beauty industry [2][8]. - Major beauty companies like L'Oréal, Estée Lauder, Shiseido, and others are actively investing in ECM-related research and development, indicating a competitive landscape [8][11]. Group 2: N-acetylneuraminic Acid (Nectar Acid) - N-acetylneuraminic acid has recently been approved by the National Medical Products Administration in China, marking its transition from experimental to a recognized cosmetic ingredient [3][15]. - This ingredient exhibits multiple biological activities, including anti-wrinkle, brightening, anti-inflammatory properties, and the ability to regulate ECM homeostasis [15][22]. Group 3: Mechanisms and Efficacy - N-acetylneuraminic acid significantly enhances collagen gene promoter activity, leading to a 252% increase in type I collagen synthesis at a concentration of 0.2% [18]. - It acts as a stabilizer for ECM by neutralizing reactive oxygen species (ROS) and inhibiting matrix metalloproteinases (MMP-1, MMP-3, MMP-9), thereby reducing collagen degradation [20][22]. Group 4: Market Potential and Applications - The successful incorporation of N-acetylneuraminic acid into the cosmetic ingredient directory opens up new market opportunities and enhances its commercial value [26][27]. - The ingredient's dual application in both topical and oral beauty products aligns with traditional Asian wellness practices, providing a strong foundation for cross-category integration [26][28]. Group 5: Research and Development - The company has invested over 30 million yuan in the industrialization of N-acetylneuraminic acid, overcoming traditional extraction challenges to achieve high purity and yield [28][29]. - Ongoing research focuses on multi-omics studies to validate the ingredient's efficacy across various biological pathways, enhancing its appeal in the anti-aging market [25][34].

嘉必优生物技术（武汉）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688089 证券简称：嘉必优 公告编号：2025-055 ? 股东持股的基本情况 截止本公告披露日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）股东马涛先生持有公司股份 157,373 股，占公司总股本的 0.0935%。其中 易买入股份，34,392 股来源于公司 2022 年度资本公积转增股本，均为无限售流 通股。 ? 减持计划的主要内容 马涛先生因个人资金需求，拟于减持计划披露之日起 15 个交易日后的 3 个 月内通过集中竞价方式减持其所持有的公司股份，合计数量不超过 150,000 股， 即不超过公司总股本的 0.0891%。 ? 特别说明 马涛先生系原公司第三届高级管理人员，现已卸任高级管理人员职位届满 6 个月，按照现行法律法规要求无需披露减持计划，但因公司拟并购上海欧易生物 医学科技有限公司 63.2134%股权项目签署了承诺函："自本次交易复牌之日起 ...